Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Mental Disease

PUBLISHER: Fairfield Market Research | PRODUCT CODE: 1385666

Cover Image

PUBLISHER: Fairfield Market Research | PRODUCT CODE: 1385666

Fibromyalgia Antidepressants Market - Global Industry Analysis, Size, Share, Growth, Trends, & Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America & Middle East & Africa)

PUBLISHED:
PAGES: 231 Pages
DELIVERY TIME: 2-5 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PPT Slides/PDF & Excel (Enterprise License)
USD 4995

Add to Cart

Description

Table of Contents

The global revenue from the fibromyalgia antidepressants market reached approximately US$ 520 million in 2024, with a projected compound annual growth rate (CAGR) of 9.7%. The market is expected to reach a valuation of approximately US$ 1000 million by the end of 2031.

Factors Driving Market Growth

The growth of the global fibromyalgia antidepressants market is influenced by various factors:

Research on Cannabinoid Therapy: Ongoing research on the therapeutic potential of modifying the endocannabinoid system for fibromyalgia (FM) treatment is contributing to market growth. The endocannabinoid system plays a role in pain and stress control, and studies are exploring the use of cannabinoid drugs for FM.

Presence of Low-Cost SNRI Drugs: Some drugs, like venlafaxine (an SNRI), have shown potential for FM treatment, and their affordability compared to other options makes them cost-effective alternatives.

Global Guidelines: International guidelines on blood sample collection and storage are improving the accuracy of glucose analysis, benefiting the market.

Challenges to Market Growth

Alternative Therapies: Alternative therapies, such as acupuncture and neural stimulation, are being explored for FM treatment, which could limit the growth of the antidepressants market.

Invasiveness: The invasiveness of some treatment methods, like blood collection with glucose analysis tubes, may lead patients to seek less invasive alternatives.

Cost of Care: The high cost of care, especially in the case of glucose analysis strips, can deter patients from using antidepressant treatments.

Country-wise Insights

United States: Rigorous R&D activities and regulatory-approved treatment modalities drive market growth in the U.S. Approved drugs for FM treatment include duloxetine, MLN, and PGB, while opioids are not authorized for this purpose. Novel product launches and approvals are expected to further expand the market.

Germany: Established recommendations and guidelines from medical societies contribute to market growth. Popular FM medications in Germany include Pregabalin, Duloxetine, and Amitriptyline, despite their limited efficacy.

China: Fibromyalgia responds well to traditional Chinese medicine, and the country is adopting combination therapy approaches. Increasing research on traditional Chinese medicine's efficacy and growing disease awareness are boosting the market.

Competition Landscape

The global fibromyalgia antidepressants market features both established and emerging market players investing in research and development for cutting-edge treatments. The pipeline of potential products in clinical studies is substantial, indicating growth potential.

Key companies profiled in the market include:

  • Pfizer Inc
  • Eli Lilly and Company
  • AbbVie, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Johnson & Johnson Services, Inc
  • Sanofi
  • GlaxoSmithKline plc.
  • Bayer AG
  • TONIX Pharmaceuticals Holdings Corp
  • Virios Therapeutics, Inc.
  • Aptinyx Inc.
  • FSD Pharma

Key Segments Covered in Fibromyalgia Antidepressants Industry Research

Drug:

  • Venlafaxine
  • Duloxetine HCl
  • Milnacipran HCl
  • Others

Distribution Channel:

  • Hospitals Pharmacies
  • Drug Stores
  • Retail Pharmacies
  • Online Pharmacies

Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa
Show more

Table of Contents

1. Executive Summary

  • 1.1. Global Fibromyalgia Antidepressants Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2023
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. COVID-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Impact of Ukraine-Russia Conflict
  • 2.7. Economic Overview
    • 2.7.1. World Economic Projections
  • 2.8. PESTLE Analysis

3. Global Fibromyalgia Antidepressants Market Outlook, 2018 - 2031

  • 3.1. Global Fibromyalgia Antidepressants Market Outlook, by Drug, Value (US$ Mn), 2018 - 2031
    • 3.1.1. Key Highlights
      • 3.1.1.1. Venlafaxine
      • 3.1.1.2. Duloxetine HCl
      • 3.1.1.3. Milnacipran HCl
      • 3.1.1.4. Others
  • 3.2. Global Fibromyalgia Antidepressants Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 3.2.1. Key Highlights
      • 3.2.1.1. Hospitals Pharmacies
      • 3.2.1.2. Drug Stores
      • 3.2.1.3. Retail Pharmacies
      • 3.2.1.4. Online Pharmacies
  • 3.3. Global Fibromyalgia Antidepressants Market Outlook, by Region, Value (US$ Mn), 2018 - 2031
    • 3.3.1. Key Highlights
      • 3.3.1.1. North America
      • 3.3.1.2. Europe
      • 3.3.1.3. Asia Pacific
      • 3.3.1.4. Latin America
      • 3.3.1.5. Middle East & Africa

4. North America Fibromyalgia Antidepressants Market Outlook, 2018 - 2031

  • 4.1. North America Fibromyalgia Antidepressants Market Outlook, by Drug, Value (US$ Mn), 2018 - 2031
    • 4.1.1. Key Highlights
      • 4.1.1.1. Venlafaxine
      • 4.1.1.2. Duloxetine HCl
      • 4.1.1.3. Milnacipran HCl
      • 4.1.1.4. Others
  • 4.2. North America Fibromyalgia Antidepressants Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 4.2.1. Key Highlights
      • 4.2.1.1. Hospitals Pharmacies
      • 4.2.1.2. Drug Stores
      • 4.2.1.3. Retail Pharmacies
      • 4.2.1.4. Online Pharmacies
    • 4.2.2. BPS Analysis/Market Attractiveness Analysis
  • 4.3. North America Fibromyalgia Antidepressants Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 4.3.1. Key Highlights
      • 4.3.1.1. U.S. Fibromyalgia Antidepressants Market by Drug, Value (US$ Mn), 2018 - 2031
      • 4.3.1.2. U.S. Fibromyalgia Antidepressants Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 4.3.1.3. Canada Fibromyalgia Antidepressants Market by Drug, Value (US$ Mn), 2018 - 2031
      • 4.3.1.4. Canada Fibromyalgia Antidepressants Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 4.3.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Fibromyalgia Antidepressants Market Outlook, 2018 - 2031

  • 5.1. Europe Fibromyalgia Antidepressants Market Outlook, by Drug, Value (US$ Mn), 2018 - 2031
    • 5.1.1. Key Highlights
      • 5.1.1.1. Venlafaxine
      • 5.1.1.2. Duloxetine HCl
      • 5.1.1.3. Milnacipran HCl
      • 5.1.1.4. Others
  • 5.2. Europe Fibromyalgia Antidepressants Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 5.2.1. Key Highlights
      • 5.2.1.1. Hospitals Pharmacies
      • 5.2.1.2. Drug Stores
      • 5.2.1.3. Retail Pharmacies
      • 5.2.1.4. Online Pharmacies
    • 5.2.2. BPS Analysis/Market Attractiveness Analysis
  • 5.3. Europe Fibromyalgia Antidepressants Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 5.3.1. Key Highlights
      • 5.3.1.1. Germany Fibromyalgia Antidepressants Market by Drug, Value (US$ Mn), 2018 - 2031
      • 5.3.1.2. Germany Fibromyalgia Antidepressants Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 5.3.1.3. U.K. Fibromyalgia Antidepressants Market by Drug, Value (US$ Mn), 2018 - 2031
      • 5.3.1.4. U.K. Fibromyalgia Antidepressants Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 5.3.1.5. France Fibromyalgia Antidepressants Market by Drug, Value (US$ Mn), 2018 - 2031
      • 5.3.1.6. France Fibromyalgia Antidepressants Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 5.3.1.7. Italy Fibromyalgia Antidepressants Market by Drug, Value (US$ Mn), 2018 - 2031
      • 5.3.1.8. Italy Fibromyalgia Antidepressants Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 5.3.1.9. Turkey Fibromyalgia Antidepressants Market by Drug, Value (US$ Mn), 2018 - 2031
      • 5.3.1.10. Turkey Fibromyalgia Antidepressants Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 5.3.1.11. Russia Fibromyalgia Antidepressants Market by Drug, Value (US$ Mn), 2018 - 2031
      • 5.3.1.12. Russia Fibromyalgia Antidepressants Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 5.3.1.13. Rest of Europe Fibromyalgia Antidepressants Market by Drug, Value (US$ Mn), 2018 - 2031
      • 5.3.1.14. Rest of Europe Fibromyalgia Antidepressants Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 5.3.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Fibromyalgia Antidepressants Market Outlook, 2018 - 2031

  • 6.1. Asia Pacific Fibromyalgia Antidepressants Market Outlook, by Drug, Value (US$ Mn), 2018 - 2031
    • 6.1.1. Key Highlights
      • 6.1.1.1. Venlafaxine
      • 6.1.1.2. Duloxetine HCl
      • 6.1.1.3. Milnacipran HCl
      • 6.1.1.4. Others
  • 6.2. Asia Pacific Fibromyalgia Antidepressants Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 6.2.1. Key Highlights
      • 6.2.1.1. Hospitals Pharmacies
      • 6.2.1.2. Drug Stores
      • 6.2.1.3. Retail Pharmacies
      • 6.2.1.4. Online Pharmacies
    • 6.2.2. Others BPS Analysis/Market Attractiveness Analysis
  • 6.3. Asia Pacific Fibromyalgia Antidepressants Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 6.3.1. Key Highlights
      • 6.3.1.1. China Fibromyalgia Antidepressants Market by Drug, Value (US$ Mn), 2018 - 2031
      • 6.3.1.2. China Fibromyalgia Antidepressants Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 6.3.1.3. Japan Fibromyalgia Antidepressants Market by Drug, Value (US$ Mn), 2018 - 2031
      • 6.3.1.4. Japan Fibromyalgia Antidepressants Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 6.3.1.5. South Korea Fibromyalgia Antidepressants Market by Drug, Value (US$ Mn), 2018 - 2031
      • 6.3.1.6. South Korea Fibromyalgia Antidepressants Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 6.3.1.7. India Fibromyalgia Antidepressants Market by Drug, Value (US$ Mn), 2018 - 2031
      • 6.3.1.8. India Fibromyalgia Antidepressants Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 6.3.1.9. Southeast Asia Fibromyalgia Antidepressants Market by Drug, Value (US$ Mn), 2018 - 2031
      • 6.3.1.10. Southeast Asia Fibromyalgia Antidepressants Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 6.3.1.11. Rest of Asia Pacific Fibromyalgia Antidepressants Market by Drug, Value (US$ Mn), 2018 - 2031
      • 6.3.1.12. Rest of Asia Pacific Fibromyalgia Antidepressants Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 6.3.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Fibromyalgia Antidepressants Market Outlook, 2018 - 2031

  • 7.1. Latin America Fibromyalgia Antidepressants Market Outlook, by Drug, Value (US$ Mn), 2018 - 2031
    • 7.1.1. Key Highlights
      • 7.1.1.1. Venlafaxine
      • 7.1.1.2. Duloxetine HCl
      • 7.1.1.3. Milnacipran HCl
      • 7.1.1.4. Others
  • 7.2. Latin America Fibromyalgia Antidepressants Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 7.2.1.1. Hospitals Pharmacies
      • 7.2.1.2. Drug Stores
      • 7.2.1.3. Retail Pharmacies
      • 7.2.1.4. Online Pharmacies
    • 7.2.2. BPS Analysis/Market Attractiveness Analysis
  • 7.3. Latin America Fibromyalgia Antidepressants Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 7.3.1. Key Highlights
      • 7.3.1.1. Brazil Fibromyalgia Antidepressants Market by Drug, Value (US$ Mn), 2018 - 2031
      • 7.3.1.2. Brazil Fibromyalgia Antidepressants Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 7.3.1.3. Mexico Fibromyalgia Antidepressants Market by Drug, Value (US$ Mn), 2018 - 2031
      • 7.3.1.4. Mexico Fibromyalgia Antidepressants Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 7.3.1.5. Argentina Fibromyalgia Antidepressants Market by Drug, Value (US$ Mn), 2018 - 2031
      • 7.3.1.6. Argentina Fibromyalgia Antidepressants Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 7.3.1.7. Rest of Latin America Fibromyalgia Antidepressants Market by Drug, Value (US$ Mn), 2018 - 2031
      • 7.3.1.8. Rest of Latin America Fibromyalgia Antidepressants Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 7.3.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Fibromyalgia Antidepressants Market Outlook, 2018 - 2031

  • 8.1. Middle East & Africa Fibromyalgia Antidepressants Market Outlook, by Drug, Value (US$ Mn), 2018 - 2031
    • 8.1.1. Key Highlights
      • 8.1.1.1. Venlafaxine
      • 8.1.1.2. Duloxetine HCl
      • 8.1.1.3. Milnacipran HCl
      • 8.1.1.4. Others
  • 8.2. Middle East & Africa Fibromyalgia Antidepressants Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 8.2.1. Key Highlights
      • 8.2.1.1. Hospitals Pharmacies
      • 8.2.1.2. Drug Stores
      • 8.2.1.3. Retail Pharmacies
      • 8.2.1.4. Online Pharmacies
    • 8.2.2. BPS Analysis/Market Attractiveness Analysis
  • 8.3. Middle East & Africa Fibromyalgia Antidepressants Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 8.3.1. Key Highlights
      • 8.3.1.1. GCC Fibromyalgia Antidepressants Market by Drug, Value (US$ Mn), 2018 - 2031
      • 8.3.1.2. GCC Fibromyalgia Antidepressants Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 8.3.1.3. South Africa Fibromyalgia Antidepressants Market by Drug, Value (US$ Mn), 2018 - 2031
      • 8.3.1.4. South Africa Fibromyalgia Antidepressants Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 8.3.1.5. Egypt Fibromyalgia Antidepressants Market by Drug, Value (US$ Mn), 2018 - 2031
      • 8.3.1.6. Egypt Fibromyalgia Antidepressants Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 8.3.1.7. Nigeria Fibromyalgia Antidepressants Market by Drug, Value (US$ Mn), 2018 - 2031
      • 8.3.1.8. Nigeria Fibromyalgia Antidepressants Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 8.3.1.9. Rest of Middle East & Africa Fibromyalgia Antidepressants Market by Drug, Value (US$ Mn), 2018 - 2031
      • 8.3.1.10. Rest of Middle East & Africa Fibromyalgia Antidepressants Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 8.3.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. Manufacturer vs by Distribution Channel Heatmap
  • 9.2. Company Market Share Analysis, 2023
  • 9.3. Competitive Dashboard
  • 9.4. Company Profiles
    • 9.4.1. Pfizer Inc.
      • 9.4.1.1. Company Overview
      • 9.4.1.2. Product Portfolio
      • 9.4.1.3. Financial Overview
      • 9.4.1.4. Business Strategies and Development
    • 9.4.2. Eli Lilly and Company
      • 9.4.2.1. Company Overview
      • 9.4.2.2. Product Portfolio
      • 9.4.2.3. Financial Overview
      • 9.4.2.4. Business Strategies and Development
    • 9.4.3. AbbVie, Inc.
      • 9.4.3.1. Company Overview
      • 9.4.3.2. Product Portfolio
      • 9.4.3.3. Financial Overview
      • 9.4.3.4. Business Strategies and Development
    • 9.4.4. Teva Pharmaceutical Industries Ltd.
      • 9.4.4.1. Company Overview
      • 9.4.4.2. Product Portfolio
      • 9.4.4.3. Financial Overview
      • 9.4.4.4. Business Strategies and Development
    • 9.4.5. Johnson & Johnson Services, Inc.
      • 9.4.5.1. Company Overview
      • 9.4.5.2. Product Portfolio
      • 9.4.5.3. Financial Overview
      • 9.4.5.4. Business Strategies and Development
    • 9.4.6. Sanofi
      • 9.4.6.1. Company Overview
      • 9.4.6.2. Product Portfolio
      • 9.4.6.3. Financial Overview
      • 9.4.6.4. Business Strategies and Development
    • 9.4.7. GlaxoSmithKline plc.
      • 9.4.7.1. Company Overview
      • 9.4.7.2. Product Portfolio
      • 9.4.7.3. Financial Overview
      • 9.4.7.4. Business Strategies and Development
    • 9.4.8. Bayer AG
      • 9.4.8.1. Company Overview
      • 9.4.8.2. Product Portfolio
      • 9.4.8.3. Financial Overview
      • 9.4.8.4. Business Strategies and Development

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!